Tahereh Damghani

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

The origin of potency and mutant-selective inhibition by bivalent ATP-allosteric EGFR inhibitors

Novel quinazoline-1, 2, 3-triazole hybrids with anticancer and MET kinase targeting properties

Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitors

Benzyl‐Triazole Derivatives of Hydrazinecarbothiamide Derivatives as Potent Tyrosinase Inhibitors: Synthesis, Biological Evaluation, Structure‐Activity Relationship and Docking …

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.

Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design.

In silico screening of c-Met tyrosine kinase inhibitors targeting nucleotide and drug-substrate binding sites of ABCB1 as potential MDR reversal agents